The primary outcome measure was urine N-telopeptide ( uNTX ) level , with secondary measures of plasma C-telopeptide ( CTX ) , quality of life ( Functional Assessment of Cancer Therapy-Bone Pain [ FACT-BP ] , Brief Pain Inventory [ BPI ] ) , progression-free survival ( PFS ) , SREs , and safety .